Mitigare® True Blue Savings Program Ends This Month
West-Ward Pharmaceuticals Inc. (now Hikma Pharmaceuticals USA Inc.) changed the Colchicine market in 2016 by introducing Mitigare® (Colchicine) 0.6mg Capsules for prophylaxis of gout flares in adults.1 Soon after the launch of Mitigare®, the company introduced the True Blue Savings program—the first and only co-pay program for Colchicine Capsules. Although the True Blue Savings program has helped many eligible gout patients save money on their Colchicine therapy over the years, the program will
end December 31, 2023.
How Mitigare® made Colchicine affordable
In 2006, the US Food and Drug Administration (FDA) announced a new initiative to promote testing of medicines in use prior to the agency’s existence. Despite the fact that Colchicine had been used to prevent gout flares for hundreds of years, unapproved formulations of the drug were banned a few years later. The FDA approved Colcrys® (colchicine, USP) 0.6 mg tablets in 2009,2 which launched at a significantly higher price than pre-existing unapproved Colchicine generics. Patients were forced to pay a premium price for Colcrys® because it was the only FDA-approved Colchicine product available at that time. The launch of Mitigare® (and the subsequent launch of Authorized Generic Colchicine Capsules) was important because it gave people with gout a reasonably priced alternative to Colcrys®.
How the True Blue Savings program helped eligible patients save on Colchicine
Although the launches of Mitigare® and Authorized Generic Colchicine Capsules helped make Colchicine therapy more affordable for people with gout, Hikma wanted to give eligible patients the opportunity to save even more. Thus, the True Blue Savings program was born. The True Blue Savings program was the first and only Colchicine co-pay program available to consumers. It offered eligible patients the opportunity to pay as little as $0 per month for their Colchicine therapy.
You may still be able to save on Mitigare®
Although the True Blue Savings program will be discontinued on December 31, 2023, you may still be able to save on Mitigare®. One possible way is with GoodRx. When on the site, search “Mitigare” to check out pricing at local pharmacies. If you are uninsured or underinsured, you may be able to access discounts on Colchicine with the InsideRx® pharmacy discount card.
Thank you for participating
Hikma Pharmaceuticals USA Inc. appreciates its valued customers and is grateful for their loyalty. Although the True Blue Savings program will end on December 31, 2023, Mitigare® and Authorized Generic Colchicine Capsules will continue to be available at pharmacies nationwide. If you have questions about Mitigare® or Authorized Generic Colchicine Capsules, please call Hikma Pharmaceuticals USA Inc. Customer Service at 1-800-631-2174.
Mitigare® is a registered trademark of Hikma Pharmaceuticals USA Inc.
All other registered trademarks are the property of their respective owners.
NOTE: This article was not written by a medical professional and is not intended to substitute for the guidance of a physician. These are not Hikma’s recommendations for gout flare prevention, but rather facts and data collected from various reliable medical sources. For a full list of resources and their attributing links, see below.